• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott gains on Q2 earnings beat, raised outlook

Abbott gains on Q2 earnings beat, raised outlook

July 17, 2019 By Brad Perriello

AbbottAbbott (NYSE:ABT) shares gained today in pre-market trading after the healthcare giant beat the second-quarter consensus earnings forecast and raised its outlook on the rest of the year.

Abbott Park, Ill.-based Abbott posted profits of $1.0 billion, or 56¢ per share, on sales of $7.98 billion for the three months ended June 30, for a bottom-line gain of 37.2% on sales growth of 2.7% compared with Q2 2018.

Adjusted to exclude one-time items, earnings per share were 82¢, two pennies ahead of the consensus on Wall Street, where analysts were looking for revenues of $8.0 billion.

“Our sales growth accelerated and is sustainable,” chairman & CEO Miles White said in prepared remarks. “We have great momentum and are raising our guidance above the strong outlook we previously set for the year.”

Abbott said it now expects to post adjusted EPS of $3.21 to $3.27 this year, up from $3.15 to $3.25 previously. Organic sales growth is forecast for 7.0% to 8.0%, the company said.

Third-quarter adjusted EPS are pegged at 83¢ to 85¢, Abbott said.

ABT shares, which closed down -0.8% yesterday at $83.16 apiece, were up 1.7% to $84.60 each today in pre-market trading.

Medical device sales gain 6%

Sales for Abbott’s medical device division rose 6.4% to $3.08 billion, powered by double-digit growth in electrophysiology ($430 million, +7.6%),  heart failure ($201 million, +22.8%), structural heart ($352 million, +11.9%) and diabetes ($602 million, +28.2%).

Abbott put the spotlight on its HeartMate 3 left ventricular assist device, which won FDA approval as a destination therapy last year, and an expanded indication for the MitraClip mitral valve repair device and  as particular growth drivers.

But it was the diabetes division’s FreeStyle Libre continuous glucose monitoring device that posted the strongest growth for the medtech business, with sales up 63.9% to $433 million (nearly 72% of the total for the diabetes segment).

Filed Under: Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Abbott

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy